Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,186.74 -0.96 (-0.02%) Dow
39,037.15 +152.89 (+0.39%) Nasdaq
16,299.73 -32.83 (-0.20%) Bitcoin USD
62,538.23 -330.69 (-0.53%) CMC Crypto 200
1,331.23 +36.56 (+2.82%)
Lucid Diagnostics Inc. (LUCD)
| Previous close | 1.0300 |
| Open | 1.0000 |
| Bid | 0.9531 x 100 |
| Ask | 0.9786 x 100 |
| Day's range | 0.9600 - 1.0400 |
| 52-week range | 0.6300 - 1.8500 |
| Volume | |
| Avg. volume | 217,047 |
| Market cap | 48.082M |
| Beta (5Y monthly) | 1.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2600 |
| Earnings date | 26 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.83 |
PR NewswireLucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing the total Series B / B-1 gross proceeds to $29.8 million. The offering provides the Company with significant working cap
- PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Monday, May 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued gr
- PR Newswire
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid's EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device. T
